Rathbunioside R1 is primarily investigated for its potential anti-inflammatory and immunomodulatory properties. It has shown activity in suppressing pro-inflammatory cytokines, making it a candidate for research in autoimmune and chronic inflammatory conditions. Preliminary studies suggest it may influence cellular signaling pathways involved in immune response, particularly NF-κB and MAPK pathways. Due to its natural origin and structural complexity, it is also studied in the context of drug development for metabolic and degenerative diseases. However, its application remains largely experimental, with most data derived from in vitro and animal models. Further research is needed to evaluate bioavailability, toxicity, and therapeutic efficacy in humans.